Serena Ricciardi

1.6k total citations
27 papers, 545 citations indexed

About

Serena Ricciardi is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Serena Ricciardi has authored 27 papers receiving a total of 545 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pulmonary and Respiratory Medicine, 20 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in Serena Ricciardi's work include Lung Cancer Treatments and Mutations (19 papers), Lung Cancer Research Studies (12 papers) and Lung Cancer Diagnosis and Treatment (4 papers). Serena Ricciardi is often cited by papers focused on Lung Cancer Treatments and Mutations (19 papers), Lung Cancer Research Studies (12 papers) and Lung Cancer Diagnosis and Treatment (4 papers). Serena Ricciardi collaborates with scholars based in Italy, Lebanon and United States. Serena Ricciardi's co-authors include Filippo de Marinis, Maria Rita Migliorino, Alberto Fulvi, Bruno Gori, Antônio Rossi, Federica Tomao, Ester Del Signore, Chiara D’Antonio, Antonio Passaro and Paolo Maione and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

Serena Ricciardi

25 papers receiving 539 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Serena Ricciardi Italy 11 342 287 178 59 49 27 545
Qiong Zhao China 14 299 0.9× 196 0.7× 145 0.8× 82 1.4× 29 0.6× 28 503
L. Hart United States 11 254 0.7× 183 0.6× 220 1.2× 66 1.1× 33 0.7× 25 518
Ann W. Gramza United States 10 200 0.6× 181 0.6× 137 0.8× 52 0.9× 72 1.5× 22 552
Giuseppe Colantuoni Italy 13 317 0.9× 182 0.6× 185 1.0× 86 1.5× 42 0.9× 28 509
Hae Su Kim South Korea 12 270 0.8× 173 0.6× 147 0.8× 92 1.6× 78 1.6× 26 511
Tahsin M. Khan United States 8 344 1.0× 364 1.3× 275 1.5× 115 1.9× 51 1.0× 23 604
Luis Manuel Martínez-Barrera Mexico 10 271 0.8× 270 0.9× 158 0.9× 72 1.2× 30 0.6× 23 524
Luke Walker United States 10 272 0.8× 255 0.9× 253 1.4× 47 0.8× 30 0.6× 39 489
Ayako Mitsuma Japan 13 294 0.9× 122 0.4× 189 1.1× 41 0.7× 40 0.8× 43 532
Tamotsu Sagawa Japan 15 303 0.9× 312 1.1× 171 1.0× 40 0.7× 169 3.4× 60 698

Countries citing papers authored by Serena Ricciardi

Since Specialization
Citations

This map shows the geographic impact of Serena Ricciardi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Serena Ricciardi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Serena Ricciardi more than expected).

Fields of papers citing papers by Serena Ricciardi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Serena Ricciardi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Serena Ricciardi. The network helps show where Serena Ricciardi may publish in the future.

Co-authorship network of co-authors of Serena Ricciardi

This figure shows the co-authorship network connecting the top 25 collaborators of Serena Ricciardi. A scholar is included among the top collaborators of Serena Ricciardi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Serena Ricciardi. Serena Ricciardi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bria, Emilio, José Luís Costa, Claudio Sini, et al.. (2024). 1283P Advanced ALK-positive non-small cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database. Annals of Oncology. 35. S818–S818. 1 indexed citations
2.
Boni, Luca, et al.. (2024). MA01.03 Neoadjuvant Alectinib in Potentially Resectable Stage III ALK-Positive NSCLC: Interim Analysis of ALNEO-GOIRC-01-2020 Phase II Trial. Journal of Thoracic Oncology. 19(10). S52–S52. 1 indexed citations
3.
Cortellini, Alessio, Michele De Tursi, Serena Ricciardi, et al.. (2024). A preliminary study on the diagnostic performance of the uPath PD-L1 (SP263) artificial intelligence (AI) algorithm in patients with NSCLC treated with PD-1/PD-L1 checkpoint blockade. Pathologica. 116(4). 222–231. 2 indexed citations
4.
Minuti, Gabriele, Silvia Carpano, Ettore D’Argento, et al.. (2021). [Management of small cell lung cancer patient in the regions of Lazio, Umbria and Sardinia.]. PubMed. 112(10). 639–646. 1 indexed citations
5.
Iacono, Daniela, Maria Rita Migliorino, Lucia Grillo, et al.. (2019). Intrapatient Molecular and Histologic Heterogeneity After First-generation or Second-generation TKI Therapy of NSCLC Patients. American Journal of Clinical Oncology. 42(11). 845–850. 7 indexed citations
6.
7.
Gridelli, Cesare, Antonio Chella, Giuseppe Valmadre, et al.. (2016). Second-line Erlotinib or Intermittent Erlotinib plus Docetaxel in Male Ex-smokers with Squamous NSCLC: The TALISMAN Randomized Trial. Anticancer Research. 36(12). 6535–6540. 5 indexed citations
8.
Gori, Bruno, Serena Ricciardi, Alberto Fulvi, Ester Del Signore, & Filippo de Marinis. (2012). New Oral Multitargeted Antiangiogenics in Non-Small-Cell Lung Cancer Treatment. Future Oncology. 8(5). 559–573. 5 indexed citations
9.
Gori, Bruno, Serena Ricciardi, Ester Del Signore, Alberto Fulvi, & Filippo de Marinis. (2012). Oral tyrosine kinase inhibitors in the first-line treatment of advanced non-small cell lung cancer. Expert Opinion on Therapeutic Targets. 16(sup2). S55–S60. 3 indexed citations
10.
Gridelli, Cesare, Floriana Morgillo, Adolfo Favaretto, et al.. (2011). Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study. Annals of Oncology. 22(7). 1528–1534. 44 indexed citations
11.
Marinis, Filippo de & Serena Ricciardi. (2011). Second-line treatment options in advanced non-small cell lung cancer. European Journal of Cancer. 47. S258–S271. 5 indexed citations
12.
Gori, Bruno, et al.. (2011). New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyond. Therapeutics and Clinical Risk Management. 7. 429–429. 9 indexed citations
13.
Marinis, Filippo de, Antônio Rossi, Massimo Di Maïo, Serena Ricciardi, & Cesare Gridelli. (2011). Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines. Lung Cancer. 73(1). 1–10. 24 indexed citations
14.
Ricciardi, Serena & Filippo de Marinis. (2010). Multimodality management of non-small cell lung cancer patients with brain metastases. Current Opinion in Oncology. 22(2). 86–93. 25 indexed citations
15.
Ricciardi, Serena. (2010). Efficacy and safety of erlotinib in the treatment of metastatic non-small-cell lung cancer. PubMed. 2. 1–1. 8 indexed citations
16.
Ricciardi, Serena & Filippo de Marinis. (2009). Treatment of Bone Metastases in Lung Cancer: The Actual Role of Zoledronic Acid. Reviews on Recent Clinical Trials. 4(3). 205–211. 13 indexed citations
17.
Ricciardi, Serena & Filippo de Marinis. (2009). New Agents in Advanced Non-Small-Cell Lung Cancer Treatment. Oncology. 77(Suppl. 1). 103–112.
18.
Rossi, Antônio, Serena Ricciardi, Paolo Maione, Filippo de Marinis, & Cesare Gridelli. (2009). Pemetrexed in the treatment of advanced non-squamous lung cancer. Lung Cancer. 66(2). 141–149. 51 indexed citations
19.
Ricciardi, Serena, Federica Tomao, & Filippo de Marinis. (2009). Toxicity of Targeted Therapy in Non–Small-Cell Lung Cancer Management. Clinical Lung Cancer. 10(1). 28–35. 67 indexed citations
20.
Giovannetti, Elisa, Enrico Vasile, Carmelo Tibaldi, et al.. (2008). Correlation Between Cytidine Deaminase Genotype and Gemcitabine Deamination in Blood Samples. Nucleosides Nucleotides & Nucleic Acids. 27(6-7). 720–725. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Qiong Zhao Breakdown of academic impact, for papers by L. Hart Breakdown of academic impact, for papers by Ann W. Gramza Breakdown of academic impact, for papers by Giuseppe Colantuoni Breakdown of academic impact, for papers by Hae Su Kim Breakdown of academic impact, for papers by Tahsin M. Khan Breakdown of academic impact, for papers by Luis Manuel Martínez-Barrera Breakdown of academic impact, for papers by Luke Walker Breakdown of academic impact, for papers by Ayako Mitsuma Breakdown of academic impact, for papers by Tamotsu Sagawa
Rankless by CCL
2026